



CompleteHealth Integration Update

Highlights

- **MyFiziq - NuraLogix designs for integration completed.**
- **High impact data using facial blood flow and total body scan for chronic illness assessment.**
- **COVID-19 symptoms-assessment ready.**
- **12 companies have registered interest.**
- **2 minutes total assessment time.**

MyFiziq Limited (ASX: MYQ) (MyFiziq) would like to update shareholders with the progress and designs of the new and soon to be released **CompleteHealth** application with Canadian based NuraLogix Corporation.

As outlined to the ASX on the 15th June 2020, MyFiziq signed a Memorandum of Understanding (**MoU**) with Canadian base Nuralogix Corporations. Under the MoU, MyFiziq will be designing and developing the integrated offering, with a view to initially release it to only 2 organisations for testing and evaluation.

MyFiziq has had an influx of inquiries from Telehealth, Wellness, Pharmacy Chains, Diabetes managements organisations, Insurers, and Re-Insurers, so much so, the companies have agreed to make the application available to a greater number of these organisations than previously anticipated.








The non-invasive combined solution delivers complete privacy to the consumer, which culminates in the individual being given assessments on multiple levels, such as;


Blood pressure.
Stress levels.
Heart rate.
Heart rate variability.
Irregular heartbeat.
Respiratory rates.
Emotion.
Total body fat.
Waist to height ratio.
Waist to hip ratio.
Cardiovascular disease risk.
Type 2 diabetes risk, and
Stroke risk.

The resulting captures and data are allowing an individual the opportunity to understand their personal exposure to type 2 diabetes, cardiovascular disease, stroke, and respiratory disease that form up to 70% of deaths globally each year, not including the current pandemic. All publications and research have been published on NuraLogix website.ⁱ

Furthermore, we will allow an option for an individual to engage in an in-app COVID-19 symptoms analysis, which has been developed and tested by NuraLogix in collaboration with St. Michael's Hospital, University of Toronto, and Zhongda Hospital in China to produce an AI based model which was trained and tested on the symptom's profiles of COVID-19 patients. The model predicts the likelihood of someone having COVID-19 versus seasonal flu or cold.

CompleteHealth Presentation





Vlado Bosanac, Chief Executive Officer of MyFiziq, said:

“The team has done an exceptional job designing the new application, which will be called **CompleteHealth**. I am extremely pleased with the amount of interest this has generated from our initial ASX release. This validates our initial thoughts on the value we will bring to communities by combining these solutions.

Importantly, we are identifying several chronic disease markers that have severe implications, should the user be exposed to COVID-19. The comorbidities such as obesity, type 2 diabetes, respiratory disease and cardiovascular disease that are identified through the process are important information for the user to consider upon the evaluation being completed.”

About NuraLogix

NuraLogix is a pioneer of Affective Artificial Intelligence (AI) which is the combination of affective computing and artificial intelligence. The company has developed the world's first cloud based Affective AI Engine, DeepAffex™, which utilizes the company's proprietary facial imaging technology, Transdermal Optical Imaging (TOI™), to predict a wide array of human physiological and psychological affects using nothing more than the video camera found on any smartphone. Using this technology, the company developed the world's first smartphone app, Anura™, that can inform you about your general health and wellness in 30 seconds.

The company's objective is to use its technology to improve the lives of people everywhere.

For more information please visit: www.NuraLogix.ai

For more information contact:

Vlado Bosanac,
Chief Executive Officer
MyFiziq Limited
E: admin@myfiziq.com

Steven Richards,
Chief Financial Officer
MyFiziq Limited
E: admin@myfiziq.com

About MyFiziq:

MyFiziq has developed and patented a proprietary dimensioning technology that enables its users to check, track, and assess their dimension using only a smartphone privately and accurately.

Our goal is to assist our partners by empowering their consumers with this capability. This in return gives our partners the ability to assess, assist, and communicate outcomes with their consumers when navigating day to day life. Whether this is a personal journey to better health, understanding the risk associated with



their physical condition, tracking the changes they are experiencing through training, dieting, or under medical regimes. or simply wanting to be correctly sized for a garment when shopping online. The MyFiziq technology delivers this seamlessly, privately, and cost-effectively in under one minute.

Our partner benefits from our (SAAS) Software as a service pricing solution, that reduces with scale. Integration is made easy with the MyFiziq modular system, based on multiple (SDK's) software development kits, allowing a partner to select the functions, measurements, and displays to suit their individual needs.

MyFiziq has developed this capability by leveraging the power of Computer Vision, Machine Learning, and patented algorithms, to process these images on secure, enterprise-level infrastructure, delivering an end-to-end experience that is unrivaled in the industry. MyFiziq simplifies the collection of measurements and removes the human error present in traditional methods.

For more information please visit: www.myfiziq.com

*This announcement has been approved by the board of MyFiziq Limited.

ⁱ <https://www.nuralogix.ai/research>